Paul Thompson, MD
Cardiovascular Disease · Hartford, CTNPI 1578590691
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $87,470 of the $107,944 with a category attached, or 81.0%. It is spread thinly across 19 manufacturers, the largest accounting for just 23.8%. Reporting peaked in 2019 at $86,466 and has fallen 99.9% since, to $73 in 2025. Among cardiovascular disease clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 143 payments — averaging $754.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amarin Pharma, Inc.$26K
- Amgen$22K
- Boehringer Ingelheim$21K
- Sanofi-aventis U.S. LLC$16K
- Lilly USA, LLC$12K
- Regeneron Healthcare Solutions, Inc.$7K
- plus $4K from 13 others
Across 43 payments — averaging $5062.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$150K
- Amgen$50K
- Amarin Pharma, Inc.$9K
- Esperion Therapeutics, Inc.$7K
- Regeneron$1K
What the payments were for
- Consulting fees$9,8459%
- Speaking & faculty fees$87,47081%
- Travel & lodging$6,7036%
- Food & beverage$3,9004%
- Education$260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amarin Pharma, Inc. | 29 | $25,696 |
| Amgen | 36 | $22,304 |
| Boehringer Ingelheim | 19 | $21,124 |
| Sanofi-aventis U.S. LLC | 16 | $16,432 |
| Lilly USA, LLC | 8 | $12,044 |
| Regeneron Healthcare Solutions, Inc. | 6 | $6,546 |
| Novartis | 2 | $1,942 |
| Kowa Pharmaceuticals America, Inc. | 3 | $1,126 |
| Kaneka Medical America LLC | 2 | $259 |
| Medtronic | 1 | $124 |
| Johnson & Johnson | 6 | $85 |
| E.r. Squibb & Sons, L.L.C. | 3 | $69 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $69 |
| Pfizer | 2 | $27 |
| CSL Behring | 1 | $23 |
| Esperion Therapeutics, Inc. | 1 | $23 |
| Novo Nordisk | 1 | $20 |
| Bardy Diagnostics, Inc. | 1 | $18 |
| Akcea Therapeutics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$107,944 in reported general payments places this provider in the 95th percentile of 415 cardiovascular disease providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 11 | $273,411 |
| Repatha SureclickEvolocumab | 274 | $215,735 |
| Praluent PenAlirocumab | 103 | $71,576 |
| JardianceEmpagliflozin | 29 | $43,381 |
| EliquisApixaban | 32 | $28,090 |
| OzempicSemaglutide | 29 | $25,492 |
| NexletolBempedoic Acid | 32 | $19,607 |
| VascepaIcosapent Ethyl | 23 | $13,987 |
| Ezetimibe | 179 | $3,320 |
| Rosuvastatin Calcium | 96 | $1,020 |
| Atorvastatin Calcium | 43 | $407 |
| Metoprolol Succinate | 33 | $393 |
| Digoxin | 16 | $317 |
| Losartan Potassium | 27 | $228 |
| Amlodipine Besylate | 24 | $200 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $27 | $301,50043 claims |
| Boehringer IngelheimJardiance | $21,124 | $43,38129 claims |
| Novo NordiskOzempic | $20 | $25,49229 claims |
| Esperion Therapeutics, Inc.Nexletol | $23 | $19,60732 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 415 cardiovascular disease providers in Connecticut.
Other cardiovascular disease in Hartford
- Stephanie SaucierHartford$243K
- Antonio FernandezHartford$113K
- Richard SoucierHartford$97K
- Atique MirzaHartford$29K
- Sean McMahonHartford$23K
- Lonny ReismanHartford$22K
- David HenryHartford$13K
- Nihar DesaiNew Haven$1.4M
- Brett NowlanBloomfield$798K
- Jeffery TestaniNew Haven$546K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.